A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

Official Title

A Phase IB/II, 2-stage, Open-label, Multicentre Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer

Summary:

This study is designed to determine the efficacy and safety of durvalumab in combination with paclitaxel and durvalumab in combination with novel oncology therapies with or without paclitaxel for first-line metastatic triple negative breast cancer.

Trial Description

Primary Outcome:

  • Incidence of adverse events
  • Laboratory findings
Secondary Outcome:
  • Objective response rate (ORR)
  • Progression-free survival (PFS).
  • Duration of response (DoR)
  • Overall survival (OS)
  • Serum concentration of durvalumab and serum or plasma concentration of novel oncology therapies
  • Presence of anti-drug antibodies (ADAs) for durvalumab and applicable novel oncology therapies
This is a Phase IB/II, 2-stage, open-label, multicentre study to determine the efficacy and safety of durvalumab in combination with novel oncology therapies (i.e. therapies designed for immune modulation) with or without paclitaxel and durvalumab+ paclitaxel as first-line treatment in patients with metastatic triple negative breast cancer (TNBC). The study is designed to concurrently evaluate potential novel treatment combinations with clinical promise using a 2-stage approach. Part 1 is a Phase IB study of safety and initial efficacy, and Part 2 is a Phase II study. The treatment regimens evaluated in Part 2 will depend on the evaluation of safety and efficacy outcomes in Part 1.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society